Literature DB >> 2084145

Mediation of prolonged increases in nasal mucosal blood flow by calcitonin gene-related peptide (CGRP).

S P Rangi1, S Sample, M H Serwonska, G A Lenahan, E J Goetzl.   

Abstract

Calcitonin gene-related peptide (CGRP) is a vasoactive and smooth muscle contractile neuropeptide, which is released during human nasal allergic reactions. Mean values for nasal blood flow (NBF), quantified in each nostril by a laser Doppler technique, varied no more than +/- 25% of a mean initial reading in normal human subjects over 4 hr in a controlled environment. Intranasal administration of multiple doses of CGRP to 17 normal subjects stimulated significant mean increases in NBF at 30-1000 ng of CGRP, with maximal mean rises of 86-130% after 100 and 300 ng of CGRP. Delivery of incremental doses of CGRP every 30 min for 2 hr evoked repetitive responses without tachyphylaxis. A single vasoactive dose of CGRP, which achieved nasal fluid concentrations similar to those elicited by antigen challenge, elicited the sensation of nasal obstruction in most subjects at 1 hr and for up to 4 hr after CGRP, without elevating nasal fluid concentrations of histamine. CGRP thus is a potent histamine-independent mediator of allergic reactions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2084145     DOI: 10.1007/BF00917475

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  12 in total

Review 1.  Calcitonin gene-related peptide: novel neuropeptide.

Authors:  E C Goodman; L L Iversen
Journal:  Life Sci       Date:  1986-06-16       Impact factor: 5.037

2.  Evaluation of a radioimmunoassay for histamine measurement in biologic fluids.

Authors:  P McBride; D Bradley; M Kaliner
Journal:  J Allergy Clin Immunol       Date:  1988-10       Impact factor: 10.793

3.  Effect of intranasal histamine on nasal mucosal blood flow and the antidiuretic activity of desmopressin.

Authors:  L S Olanoff; C R Titus; M S Shea; R E Gibson; C D Brooks
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

4.  Inotropic effects of calcitonin gene-related peptide, vasoactive intestinal polypeptide and somatostatin on the human right atrium in vitro.

Authors:  A Franco-Cereceda; L Bengtsson; J M Lundberg
Journal:  Eur J Pharmacol       Date:  1987-01-28       Impact factor: 4.432

5.  Effect of calcitonin and calcitonin gene-related peptide on pancreatic functions in man.

Authors:  C Beglinger; E Koehler; W Born; J A Fischer; U Keller; L E Hanssen; K Gyr
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

6.  The laser Doppler flowmeter for measuring microcirculation in human nasal mucosa.

Authors:  P Olsson; M Bende; P Ohlin
Journal:  Acta Otolaryngol       Date:  1985 Jan-Feb       Impact factor: 1.494

7.  Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones.

Authors:  M E Kraenzlin; J L Ch'ng; P K Mulderry; M A Ghatei; S R Bloom
Journal:  Regul Pept       Date:  1985-03

8.  The actions of calcitonin gene related peptide and vasoactive intestinal peptide as vasodilators in man in vivo and in vitro.

Authors:  S M Thom; A D Hughes; P Goldberg; G Martin; M Schachter; P S Sever
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

9.  Allergic reaction of the human nasal mucosa studied with laser Doppler flowmetry.

Authors:  S Juliusson; M Bende
Journal:  Clin Allergy       Date:  1987-07

10.  Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigen.

Authors:  K B Walker; M H Serwonska; F H Valone; W S Harkonen; O L Frick; K H Scriven; W D Ratnoff; J G Browning; D G Payan; E J Goetzl
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

View more
  1 in total

1.  Influence of TASP-V, a novel neuropeptide Y (NPY) Y2 agonist, on nasal and bronchial responses evoked by histamine in anaesthetized pigs and in humans.

Authors:  D D Malis; E Grouzmann; D R Morel; M Mutter; J S Lacroix
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.